Yeni İnhalasyon Ajanları ve Hepatotoksisite

Yıl 2011, Cilt: 20 Sayı: 4, 270 - 277, 01.12.2011

Yasemin Güneş

Öz

Halotana bağlı hepatoksisite kapsamlı bir şekilde incelenmiştir. Obezite, kadın cinsiyet, ilaç allerjisi öyküsü ve anestezik ajanlara birden fazla maruz kalınması risk faktörlerini içerir. Anestezik ajanlardan halotan, enfluran, izofluran ve desfluran insanlarda metabolik hepatosellüler hasara neden olabilir. Sevofluranın daha az metabolize edilmesi, ana metabolitinin farklı olması ve hızla glukuronidasyona uğraması nedeniyle halotandan daha düşük oranda hepatotoksik olması beklenir. Bu makalede yeni inhalasyon ajanları ile ilişkili postoperatif karaciğer fonksiyon bozukluğu yeniden gözden geçirilmiştir.

Anahtar Kelimeler

Sevofluron, desfluran, hepatoksisite

New Inhalation Agents and Hepatotoxicity

Öz

Hepatotoxicity with halothane inhalation has been studied extensively. Risk factors include obesity, female sex, a history of drug allergies, and multiple exposures to anesthetic agents. Anesthetic agents including halothane, enflurane, isoflurane, and desflurane can produce metabolic hepatocellular injury in humans to a variable extent. Sevoflurane is expected to be less hepatotoxic than halothane because it is metabolized less, and the main metabolite is different and rapidly glucuronated. Cross-sensitization between halothane and other volatile agents has been previously reported with isoflurane, enflurane, and desflurane. In this article, the topic of postoperative hepatic dysfunction associated with new inhalation agents is revisited.

Anahtar Kelimeler

Hepatotoxicity, inhalation agents

Kaynakça

• Habibollahi P , Mahboobi N, Esmaeili S,Safari S, Dabbagh A, Alavian SM. Halothane- induced hepatitis: A forgotten issue in developing countries . Hepat Mon. 2011;11:3-6. 7. Ray DC, Drummond GB. Halothane hepatitis. Br J Anaesth 1991; 67: 84–99.
• Neuberger JM. Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines. Drug Saf. 1990 ;5:28-38. 9. Mushin W, Rosen M, Bowen D, and Campbell H (1971) Post-halothane jaundice in relation to previous administration of halothane. Br Med J 3:18–22.
• Hasan F. Isoflurane hepatotoxicity in a patient with a previous history of halothane-induced hepatitis. Hepatogastroenterology 1998; 45: 518–22.
• Dugan CM, Fullerton A, Roth RA, Ganey PE. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxıcologıcal Scıences 2011; 120: 507–518.
• Bird GL and Williams R (1989) Detection of antibodies to a halothane metabolite hepten in sera from patients with halothane-associated hepatitis. J Hepatol 9:366–373
• Martin JL, Plevak DJ, Flannery KD, Charlton M, Poterucha JJ, Humpreys CC, Derfus G, Pohl LR: Hepatotoxicity after desflurane anesthesia. Anesthesiology 1995; 83: 1125-29.
• Christ DD, Satoh H, Kenna JG, Pohl LR. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988; 16: 135–40
• Kenna JG, Neuberger J, Mieli-Vergani G, Mowat AP, Williams R. Halothane hepatitis in children. Br Med J (Clin Res Ed). 1987 9;294:1209-11.
• Kharasch ED. Metabolism and toxicity of the new anesthetic agents.
• Lehmann A, Neher M, Kiessling A, Isgro F,Koloska, A, Boldt J. Case report: Fatal hepatic failure after aortic valve replacement and sevoflurane exposure. Can J Anesth 2007; 54: 11: 917–921.
• Kharasch ED. Biotransformation of sevoflurane. Anesth Analg 1995; 81 (6 Suppl): S27–38.
• Jang Y, Kim I. Severe hepatotoxicity after sevoflurane anesthesia in a child with mild renal dysfunction. Paediatr Anaesth 2005; 15: 1140–4.
• Kharasch ED, Schroeder JL, Sheffels P, Liggitt HD. Influence of sevoflurane on the metabolism and renal effects of compound A in rats. Anesthesiology 2005; 103: 1183–8.
• Zheng XH, Begay C, Lind RC, Gandolfi AJ. Humoral immune response to a sevoflurane degradation product in the guinea pig following inhalation exposure. Drug Chem Toxicol 2001; 24: 339–46.
• Darling JR, Murray JM, McBride DR, Trinick TR, Fee JPH. Serum glutathione S-transferase concentrations and creatinine clearance after sevoflurane anaesthesia. Anaesthesia 1997;52:121-126.
• Ogawa M, Doi K, Mitsufuji T, Satoh K, Takatori T.Drug induced hepatitis following sevoflurane anesthesia in a child]. Masui. 1991;40:1542-5.
• Singhal S, Gray T, Guzman G, Verma A, Anand K. Sevoflurane Hepatotoxicity: A Case Report of Sevoflurane Hepatic Necrosis and Review of the Literature. Am J Ther. 2010;17:219-22
• Bruun LS, Elkjaer S, Bitsch-Larsen,D, Andersen O. Hepatic failure in a child after acetaminophen and sevoflurane exposure. Anesth Analg 2001;92:1446–8.
• 26-Laster MJ, Gong D, Kerschmann RL, Eger EI 2nd, Martin JL. Acetaminophen predisposes to renal and hepatic injury from compound A in the fasting rat. Anesth Analg. 1997; 84:169-72.
• Arslan M, Kurtipek O, Dogan AT, Unal Y, Kizil Y, Nurlu N, Kamaci S, Kavutcu M. Comparison of effects of anaesthesia with desflurane and enflurane on liver function. Singapore Med J 2009;50: 73-7.
• Chung PC, Chiou SC, Lien JM, Li AH, Wong CH. Reproducible hepatic dysfunction following separate anesthesia with sevoflurane and desflurane. Chang Gung Med J 2003;. 26:357-61.
• Berghaus TM. Baron A, Geter A; Lamerz R. Paumgartner, G, Conzen P. Hepatotoxicity Following Desflurane Anesthesia. Hepatology 1999; 29: 613-14.
• Co te G, Bouchard S. Hepatotoxicity after Desflurane Anesthesia in a 15-month-old child with Mobius Syndrome after previous exposure to isoflurane. Anesthesiology 2007; 107:843–5.
• Windsor JA, Wynne-Jones G. Halothane hepatitis and prompt resolution with methionine therapy: case report. N Z Med J. 1988;101:502-3.